Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Demographics (1)
- AGE_C - Age category (phv00417470.v1.p1)
Disease Events (38)
- ClinicalN - Clinical N stage (phv00417474.v1.p1)
- ClinicalT - Clincal T stage (phv00417473.v1.p1)
- efs_stat - Event free survival status (event is either death by any cause or recurrence - local or distant) (phv00420531.v1.p1)
- efs_time - Time to first event (event is either death by any cause or recurrence - local or distant) (phv00420532.v1.p1)
- ER - Estrogen Receptor Status (phv00417475.v1.p1)
- FactorA - Was carboplatin given? Factor A (phv00417480.v1.p1)
- FactorB - Was Bevacizumab given? Factor B (phv00417481.v1.p1)
- GRADE - Tumor grade (phv00417472.v1.p1)
- HER2FISH - FISH Her2-neu results (phv00417478.v1.p1)
- HER2IHC - IHC Her2-neu results (phv00417479.v1.p1)
- Histological_Type - Cell or tissue type or subtype of sample (phv00417502.v1.p1)
- Histotype - Histology (phv00417503.v1.p1)
- IndRx - Treatment Arm (phv00417469.v1.p1)
- Is_Tumor - Tumor status (phv00417501.v1.p1)
- NodeAxilEXAM - Number of axillary nodes examined (phv00417487.v1.p1)
- NodeAxill - Was ALND done? (phv00417485.v1.p1)
- NodeAxilPOS - Number of positive axillary nodes (phv00417486.v1.p1)
- NodeSentEXAM - Number of SLN examined (phv00417484.v1.p1)
- NodeSentinel - Was SLN done? (phv00417482.v1.p1)
- NodeSentPOS - Number of postitive SLNs (phv00417483.v1.p1)
- pCR_BrAx - PCR in the breast and axilla (phv00417492.v1.p1)
- pCR_Breast - PCR in the breast (phv00417491.v1.p1)
- PGR - Progesterone Receptor Status (phv00417476.v1.p1)
- Primary_Metastatic_Normal - Primary tumor, metastatic tumor, or normal blood (phv00417504.v1.p1)
- Primary_Tumor_Location - Primary tumor location (phv00417506.v1.p1)
- RCB - Residual Cancer Burden (phv00417493.v1.p1)
- RCBclass - Residual Cancer Burden Class (phv00417494.v1.p1)
- StageGroup - Pathological Stage (phv00417490.v1.p1)
- StageN - N Stage (phv00417489.v1.p1)
- StageT - T Stage (phv00417488.v1.p1)
- Stra1_Stage - Clinical (pre-NST) stage (phv00417509.v1.p1)
- TsizeMAMM - Primary tumor size (mammogram) (phv00417496.v1.p1)
- TsizeMRI - Primary tumor size (MRI) (phv00417498.v1.p1)
- TsizePE - Primary tumor size (PE) (phv00417495.v1.p1)
- TsizeULTRA - Primay tumor size (ultrasound) (phv00417497.v1.p1)
- Tumor_Collection - Timing of tumor collection, pre or post surgery (phv00417508.v1.p1)
- Tumor_Subtype_PAM50 - Tumor subtype by PAM50 (phv00417510.v1.p1)
- Tumor_Treatment - Type of tumor treatment for sample (phv00417507.v1.p1)
Race and Ethnicity (2)
- RACE - Race of participant (phv00494944.v1.p1)
- WHITE - Race=White? (phv00417471.v1.p1)
Reproductive Health (1)
- MENO - Menopausal Status (phv00417477.v1.p1)
Other (11)
- Analyte_Type - Analyte Type (phv00417500.v1.p1)
- Consent - Consent group as determined by DAC; Main Study Consent (phv00417459.v1.p1)
- Sample_Body_Site - Body site where sample was collected (phv00417505.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00417499.v1.p1)
- SAMPLE_ID - Sample ID (phv00417464.v1.p1)
- Sequencing_Center - Name of the center which conducted sequencing (phv00417511.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00417461.v1.p1)
- SUBJECT_ID - De-identified subject identification number (phv00417468.v1.p1)
- SUBJECT_ID - Subject ID (phv00417458.v1.p1)
- SUBJECT_ID - Subject ID (phv00417463.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00417460.v1.p1)